LONDON, May 19, 2017 /PRNewswire/ --
Data from a pilot study using IO
Loop™ with TheraSphere® (a
90Y transarterial radioembolisation therapy)
will be presented at the World Conference on Interventional
Oncology
BTG plc (LSE: BTG), a global specialist healthcare
company, and HealthLoop, a cloud-based platform that automates
follow-up patient care, announced today their collaboration on IO
Loop™. This is an exclusive service from BTG that gives
access to a turn-key digital support platform powered by
Healthloop. IO Loop™ enables patients and their physicians to stay
connected, providing improved pre-procedural patient instructions
and ongoing follow-up care outside of the acute care setting.
This service also provides the care team with patient-reported
outcomes that help physicians meet the new reporting requirements
of Medicare Access and CHIP Authorisation Act (MACRA).
(Logo:
http://mma.prnewswire.com/media/513730/BTG_Logo.jpg )
Patients are the most underleveraged resource in the achievement
of better health outcomes. IO Loop™ empowers patients by connecting
them with their physician via a digital support platform, and fully
engages them in their treatment journey. Online engagement before,
during and after treatment has the potential to reduce physician
burden, delivering the right information at the right time. The IO
Loop™ service helps patients prepare for their treatment, track and
report any symptoms, review key treatment information at the
appropriate time, and provides a personalised follow-up care plan
with appropriate advice. This support results in a better
overall patient experience.
Lisa Hayden, Vice President,
Global Reimbursement at BTG commented: "We know that patients who
are involved in their treatment journey have the best chance of
better outcomes, and at BTG we are committed to providing solutions
to achieve this. Through IO Loop™, the first service of its kind in
interventional oncology, automated collection of patient
information, improved patient outcomes, and potentially enhanced
patient experiences can have unique benefits for healthcare
providers and help them to meet the reporting requirements of
MACRA."
Todd Johnson, HealthLoop CEO said
of the partnership: "At HealthLoop our mission is to keep
physicians and patients connected via our proven technology-enabled
engagement platform. By partnering with BTG on this important
initiative we believe that we can empower patients and offer the
best experience both for them and their healthcare provider."
The collaboration leverages BTG's leadership in interventional
oncology with HealthLoop's digital expertise in patient-centric
solutions, offering a unique service that has the potential to
differentiate and simplify interventional oncology practice.
Karen Grace, Clinical Nurse
Coordinator, Interventional Oncology at Northwestern Memorial
Hospital, Chicago commented: "At
Northwestern we have experienced the benefits of the IO Loop™
service first hand. Having ongoing access to the patient's
performance has enabled timely intervention, which in turn has
minimised complications and reduced the likelihood of re-admission.
This not only improves the quality of life of our patients but also
enables us, as healthcare providers, to deliver a higher standard
of care."
Data showing the benefits of this technology with
TheraSphere® in interventional oncology will be
presented next month at the World Conference on Interventional
Oncology (WCIO) in Boston, U.S.,
8-11 June 2017.
About BTG Interventional Oncology
BTG Interventional Oncology is transforming the way cancer is
treated with wide-ranging solutions consisting of
minimally-invasive, highly targeted therapies that can be
personalized to each patient's needs. Our products are used to
treat or provide symptomatic relief for people with cancer and
benign tumors. To learn more about BTG Interventional
Oncology, please visit: https://www.btg-im.com.
About HealthLoop
HealthLoop engages patients at home before their admission and
for weeks and months after discharge to continuously guide,
educate, and assess the status of their recovery. By automatically
sending notifications to patients, HealthLoop remotely monitors
patients and identifies those that need help, allowing clinical
teams to proactively intervene before costs and complications
escalate. Developed as an enterprise solution to support all
clinical specialties, HealthLoop's content and analytics are deeply
integrated into care management workflows. HealthLoop facilitates
over 500,000 patient interactions every month. To learn more,
please visit: http://www.healthloop.com.
About TheraSphere®
TheraSphere® 90Y glass microspheres are
specifically engineered to carry far greater power than any other
90Y liver-directed cancer therapy, delivering high doses
of radiation to liver tumors while sparing normal tissue. The
result is a powerful, targeted and well-tolerated therapy that may
lead to patients becoming eligible for curative therapies. In
the EU, Singapore, South Korea and Canada, TheraSphere® is approved
for the treatment of hepatic neoplasia. In the US,
TheraSphere® is approved under a Humanitarian Device
Exemption (HDE) for use in radiation treatment or as a neoadjuvant
to surgery or transplantation in patients with unresectable
hepatocellular carcinoma (HCC) who can have placement of
appropriately positioned hepatic arterial catheters. The device is
also indicated for HCC patients with partial or branch portal vein
thrombosis/occlusion, when clinical evaluation warrants the
treatment. The effectiveness of this device for this use has
not been demonstrated.
For full instructions for use and important safety information,
please visit http://www.therasphere.com.
SOURCE BTG Plc